Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control (CGM-Teens)
8 de agosto de 2018 atualizado por: Timothy Wysocki, Nemours Children's Clinic
The incorporation of continuous glucose sensors (CGS) into management of type 1 diabetes in adolescence could improve treatment outcomes.
But, behavioral barriers may prevent adolescents from enjoying optimal benefits from this new technology.
This study will randomize adolescents (11 to not yet 17 years old) with type 1 diabetes for at least 2 years who are not achieving targeted HbA1c levels (> 7.5%) to continue in standard care (SC), to add continuous glucose monitoring (CGM) to their care with appropriate education and medical management (CGS) or to add CGM to their care as above but to also receive support and assistance from a behavior therapist who will assist the patient and family in optimizing the adolescents' therapeutic benefit from CGS (CGS+BT).
A variety of outcomes will be measured, including blood glucose control, quality of life, and CGS satisfaction and impact.
An enrollment criterion for this study is that the adolescent must have established consistent care for type 1 diabetes at a Nemours Children's Clinic location either in Wilmington, DE, Philadelphia, PA, Orlando, FL or Pensacola, FL for at least 12 months prior to enrollment in the study.
Adolescents treated elsewhere are not eligible to enroll in the study.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
Management of type 1 diabetes mellitus (T1DM) in adolescents is very difficult and innovative approaches are needed to help them achieve better glycemic control and behavioral outcomes.
Continuous glucose sensors (CGS) have been refined progressively and provide acceptably accurate, nearly continuous estimates of glucose levels and trends.
This increased quality and quantity of glucose data could be an excellent adjunct to conventional self-monitoring of blood glucose, permitting more informed diabetes decision-making.
CGS could yield medical, educational and psychological benefits for adolescents with T1DM, but those with extremely variable self-management habits and suboptimal glycemic control may not realize these benefits readily.
We hypothesize that a targeted, family-focused behavioral intervention could optimize benefit from adding CGS to T1DM therapy for youths with glycosylated hemoglobin (HbA1c) > 7.5%.
A multi-site sample of 150 adolescents with T1DM and HbA1C of 7.5% to 10.0% will be randomized to either Standard Care for T1DM (SC), or to augmentation of SC with 9 months' use of a CGS device (CGS) or use of a CGS device supplemented with a targeted behavior therapy intervention (CGS+BT).
Multiple measures of glycemic control, glycemic variability and health care use will be obtained during the study and there will be periodic assessments of demographic factors, diabetes self-management, family relations and psychological adjustment.
Three specific aims will be addressed: 1. Evaluate whether CGS+BT yields more improvement in glycemic outcomes than CGS or SC; 2. Evaluate whether CGS+BT yields more improvement in behavioral outcomes than CGS or SC; and 3. Identify behavioral variables that mediate and moderate glycemic benefit from use of the CGS device.
The study will also compare the cost effectiveness of CGS and CGS+BT relative to SC and evaluate the predictive utility of various indices of glycemic variability in youths.
We hypothesize that, compared with SC and CGS, CGS+BT will yield significantly better biomedical outcomes (HbA1C; severe hypoglycemia; glycemic variability; proportion of glucose readings in the normal range) and behavioral outcomes (treatment adherence; parent adolescent teamwork; diabetes-related family conflict; quality of life; fear of hypoglycemia; and treatment satisfaction).
After the 9 month randomized trial, all youths will be allowed to use the CGS device during an additional 3-month continuation phase.
Statistical analyses will be based on individual growth modeling techniques.
The application capitalizes on the Principal Investigator's prior and ongoing funded research on family management of T1DM, including trials of family-focused behavioral interventions, intensive therapy regimens, and clinical evaluations of continuous glucose sensors.
The proposed study will determine whether a targeted behavioral intervention improves CGS benefits among adolescents with previously inadequate glycemic control.
These results could demonstrate that adolescents with previously suboptimal diabetic control could realize multiple benefits from CGS use if they are provided with a specialized behavioral intervention.
Tipo de estudo
Intervencional
Inscrição (Real)
116
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32207
- Nemours Children's Clinic
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
11 anos a 16 anos (Filho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Age of adolescent > 11 years and < 17 years. This age range was chosen because families of adolescents often struggle with diabetes management. Youths > 18 years old may be likely to leave home during the study.
- Diagnosis of type 1 diabetes based on the clinician's best judgment regarding the adolescent's proper diagnostic category.
- Duration of type 1 diabetes > 2 years or > 1 year with negligible stimulated c-peptide level, to exclude those with significant residual pancreatic insulin production.
- Treatment of diabetes for the 6 months prior to enrollment must consist of an intensified regimen including either daily use of an insulin pump or 3 or more daily insulin injections with pre-meal insulin doses calculated using a correction factor that considers prevailing blood glucose levels and planned carbohydrate intake.
- Adolescent must have established diabetes care at a participating Nemours Children's Clinic site as evidenced by at least two diabetes clinic visits within the prior 12 months.
- Most recent HbA1C > 7.5% and < 10.0% or mean HbA1C over the prior 12 months within that same range.
- Intention to remain in the same region and to maintain diabetes care at the enrolling center for 12 months.
- Family has working telephone service.
Exclusion Criteria:
- Youth has not used a CGM device with real-time glucose feedback for clinical management of diabetes within the prior 6 months. Intermittent or one-time use of "blinded" CGM devices for retrospective analysis only is permissible.
- Absence of any other medical conditions that, in the opinion of the attending endocrinologist, would impede completion of the study protocol.
- Youths may not be on daily glucocorticoid medications due to hyperglycemic effects of these agents.
- Not enrolled in special education for mental retardation, autism or severe behavior disorders.
- Child not in an inpatient psychiatric unit or day treatment program during the 6 months prior to enrollment.
- Primary diabetes caregiver not diagnosed or in treatment for major depression, psychosis, bipolar disorder or substance use disorder within the 6 months prior to enrollment; Child not in an inpatient psychiatric unit or day treatment program during the 6 months prior to enrollment.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Standard Care
Standard Care constitutes intensified diabetes management, an enrollment criterion for the study, consisting of either continuous subcutaneous insulin infusion (insulin pump) or multiple daily injections using a "basal-bolus" approach.
All patients must be using carbohydrate counting and have prescribed correction factors for targeted insulin bolus dose adjustments.
|
Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
|
|
Comparador Ativo: Continuous Glucose Sensor
Patients will have the same diabetes management regimen as those in the Standard Care group.
In addition they will be given a continuous glucose sensor, receive expert instruction in its use, and be guided by a physician and diabetes educator in achieving glycemic benefits through retrospective and real-time interpretation of CGS results and by learning to respond judiciously to the various CGS alarms.
|
Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
|
|
Experimental: CGS + Behavior Therapy
Patients in the use group will receive the same medical management as the Continuous Glucose Sensor group above.
In addition, they will have 6 scheduled encounters with a behavior therapist that are designed to reduce or eliminate typical behavioral and/or psychological barriers to optimal use of CGS as part of diabetes care.
|
Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Glycated Hemoglobin (HbA1c)
Prazo: Baseline, 3, 6, 9 months
|
Glycated hemoglobin (HbA1c) expressed as a percentage of hemoglobin molecules bound to glucose.
|
Baseline, 3, 6, 9 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Diabetes Technology Questionnaire-Adolescents
Prazo: Baseline, 3 6, 9 months
|
Adolescent's total score on the DTQ-Current items.
Range 30-150.
Higher scores indicate more favorable satisfaction with and impact of the package of diabetes technology (e.g.
pump, meter, CGM, etc.) in use by the patient during the prior 3 months.
|
Baseline, 3 6, 9 months
|
|
Diabetes Technology Questionnaire-Parents' Total Scores on DTQ Current Items
Prazo: Baseline, 3, 6, 9 months
|
Parents' ratings of impact and satisfaction with the diabetes devices currently in use (e.g.
pump, meter, CGM etc.) Score range from 30-150.
Higher score signify greater satisfaction and impact.
|
Baseline, 3, 6, 9 months
|
|
Blood Glucose Monitoring Communication Questionnaire-Adolescent
Prazo: Baseline, 3, 6, 9 months
|
Adolescent report of communication with parents about blood glucose monitoring and results.
Range 8-24.
Higher scores indicate more negative communication about BG results.
|
Baseline, 3, 6, 9 months
|
|
Blood Glucose Monitoring Communication Questionnaire-Parents
Prazo: Baseline, 3, 6, 9 months
|
Parents perspectives of communication with adolescent around blood glucose monitoring and results.
Score range 8-24.
Higher scores signify more negative communication about BG results.
|
Baseline, 3, 6, 9 months
|
|
Diabetes Family Conflict Scale-Adolescent
Prazo: Baseline, 3, 6, 9 months
|
Adolescent ratings of degree of diabetes-related family conflict.
Score range 19-57.
Higher scores indicate more frequent family conflict around diabetes.
|
Baseline, 3, 6, 9 months
|
|
Diabetes Family Conflict Scale-Parent
Prazo: Baseline, 3, 6, 9 months
|
Parents' ratings of degree of diabetes-related family conflict.
Score range 19-57.
Higher scores indicate more family conflict around diabetes.
|
Baseline, 3, 6, 9 months
|
|
Diabetes Family Responsibility Questionnaire-Adolescent
Prazo: Baserline, 3, 6, 9 months
|
Adolescent's self-ratings of their degree of responsibility for 38 diabetes tasks.
Score range 0-76.
Lower scores indicate greater adolescent responsibility for diabetes care.
|
Baserline, 3, 6, 9 months
|
|
Diabetes Family Responsibility Questionnaire-Parent
Prazo: Baseline, 3, 6, 9 months
|
Parent ratings of adolescent's degree of responsibility for 38 diabetes tasks.
Score range 0-76.
Lower scores indicate great adolescent responsibility for diabetes care tasks.
|
Baseline, 3, 6, 9 months
|
|
Diabetes Self Management Profile-Adolescent
Prazo: Baseline, 3, 6, 9 months
|
Adolescent self-report of diabetes management behaviors.
Score range 0-86.
Higher scores indicate more meticulous diabetes treatment adherence.
|
Baseline, 3, 6, 9 months
|
|
Diabetes Self Management Profile-Parent
Prazo: Baseline, 3, 6, 9 months
|
Parent report of adolescent's diabetes self-management behaviors.
Score range 0-86.
Higher scores indicate more meticulous diabetes treatment adherence.
|
Baseline, 3, 6, 9 months
|
|
Hypoglycemia Fear Survey-Adolescent
Prazo: Baseline, 3, 6, 9 months
|
Adolescent worry and behavior related to apprehension of low BG episodes.
Score range 24-72.
Higher scores indicate greater fear and avoidance of hypoglycemia
|
Baseline, 3, 6, 9 months
|
|
Hypoglycemia Fear Survey-Parent
Prazo: Baseline, 3, 6, 9 months
|
Parental worry and behavior related to apprehension of low BG events.
Score range 24-72.
Higher scores indicate greater parental fear and avoidance of hypoglycemia.
|
Baseline, 3, 6, 9 months
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Tim Wysocki, Ph.D., Nemours Children's Clinic Jacksonville
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de agosto de 2009
Conclusão Primária (Real)
30 de junho de 2017
Conclusão do estudo (Real)
30 de junho de 2017
Datas de inscrição no estudo
Enviado pela primeira vez
23 de julho de 2009
Enviado pela primeira vez que atendeu aos critérios de CQ
23 de julho de 2009
Primeira postagem (Estimativa)
24 de julho de 2009
Atualizações de registro de estudo
Última Atualização Postada (Real)
10 de setembro de 2018
Última atualização enviada que atendeu aos critérios de controle de qualidade
8 de agosto de 2018
Última verificação
1 de agosto de 2018
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1R01DK080831 (Concessão/Contrato do NIH dos EUA)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .